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Abstract
Although hypertension is known to be strongly associated with short-term renal allograft 
dysfunction within 5 years after a pediatric kidney transplantation （KTx）, the long-term outcomes （＞10 
years） are unclear. The present study retrospectively assessed the effect of hypertension on the estimated 
glomerular filtration rate （eGFR） decline in renal allografts over 15 years after KTx in pediatric 
recipients. Out of 49 pediatric KTx recipients, 31 with functioning grafts, i.e., an eGFR of more than 20 
mL/min/1.73m2 at 15 years after KTx, were included in the study. All the study participants completed 
the entire 15-year observation after their KTx. Recipients with any antihypertensive medications at 
5 years after KTx were defined as hypertensive recipients, whereas those without antihypertensives 
were defined as normotensive recipients. The actual mean eGFR at 15 years after KTx was 24.3 mL/
min/1.73m2 in hypertensive recipients and 53.4 mL/min/1.73m2 in normotensive recipients （P＜0.001）. 
The eGFR decline rate of the allograft among hypertensive recipients was distinct between the 10- and 
15-year post-transplantation time points. In conclusion, our results demonstrated that hypertension had 
a significant negative impact on long-term pediatric renal allograft function and showed characteristic 
late deterioration 10 years after transplantation. Our findings suggest that hypertension may be a cause 
rather than a consequence of renal allograft dysfunction over time and emphasize the importance of 
longer post-transplantation follow-up （＞10 years） to clarify the influence of hypertension on graft 
function. Larger, prospective, long-term studies, including multidisciplinary early and sustainable blood 
pressure control trials, are warranted.
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Ⅰ．Introduction
 Hypertension after kidney transplantation （KTx） in 
pediatric recipients is common, with a prevalence of 60-
90%, 50-70%, and 40-60% at 3 months, 1 year, and 5 to 
10 years post-KTx, respectively［1-6］. This trend has not 
changed for decades［7,8］. Ambulatory blood pressure 
monitoring （ABPM） and left ventricular hypertrophy 
（LVH） detected by echocardiogram have revealed 
that post-KTx hypertension in pediatric recipients 
continues to be underrecognized, underestimated, and 
suboptimally controlled［5,9-13］. Uncontrolled and 
persistent hypertension poses a pressing clinical issue: 
its effect on renal allograft outcomes together with 
cardiovascular complications later in the patients’ life
［14,15］. In short-term studies, hypertension within 
months or a year after KTx in pediatric recipients has 
been shown to be strongly and independently associated 
with allograft dysfunction up to 5 years post-KTx［1-
3,7,16-18］. However, in longer observation periods of 
more than 5 to 10 years, the results are still inconclusive
［4,5,11,12,19-23］. All previous long-term studies 
have used statistical predictions of the graft survival 
rates based on the data of various observation periods 
in individual study participants. However, the actual 
chronological changes in graft function, i.e., the annual 
estimated glomerular filtration rate （eGFR） decline 
pattern, in both recipients with and without hypertension 
have not been reported. 
 The present observational study aimed to examine 
the effect of pediatric post-KTx hypertension on long-
term graft function and its chronological course, and 
retrospectively analyzed the renal allograft outcomes 
associated with pediatric post-KTx hypertension based 
on 15-year longitudinal follow-up of a Japanese regional 
cohort. 
Ⅱ．Patients and methods
 This study received ethics approval from Prefectural 
Okinawa Nanbu and Children’s Medical Center’s 
Institutional Review Board （ONCMC-IRB, No.29, 
January 19, 2017）. Publication of the details of this 
study was also approved by the ONCMC-IRB. Informed 
consent was obtained from all the study participants 
after explaining the manner in which the study was to be 
conducted and the publication of the findings. 
 ［Settings and participants］ The present study 
was a retrospective, observational study conducted 
at two affiliated hospitals. Between August 1987 
and November 2002, 49 pediatric patients requiring 
renal replacement therapy （RRT） by 16 years of age 
underwent their first KTx at Prefectural Okinawa Chubu 
Hospital （OCH）, the regional center for pediatric KTx 
at that time. After the post-KTx follow-up at OCH, all 
49 recipients were transferred to a newly developed 
pediatric end stage kidney disease （ESKD） program 
within Prefectural Okinawa Nanbu and Children’s 
Medical Center （ONCMC） in April 2006. Continued 
pre- and post-KTx clinical care for all the recipients 
were organized by the same pediatric nephrologist who 
moved from OCH to ONCMC, together with other 
pediatric nephrologists at ONCMC and transplant 
surgeons at OCH. Of the 49 recipients, 5 died with 
functioning grafts, 8 resumed dialysis within 15 years 
after KTx （including 2 retransplant recipients, both 
of whom were excluded from this study）. Five more 
recipients nearly required RRT due to an eGFR of 
20 mL/min/1.73m2 or less at 15 years post-KTx. 
The remaining 31 patients who had a functioning 
renal allograft （eGFR ＞20 mL/min/1.73m2） at 15 
years post-KTx were included in this study. The final 
observation point of the latest participant enrolled in this 
study was December 2017. 
 In this study, hypertension was defined as the 
use of antihypertensive medications. Recipients with 
regular antihypertensives at 5 years post-KTx were 
defined as hypertensive recipients （HRs） whereas 
those without any antihypertensives at 5 years post-
KTx were defined as normotensive recipients （NRs）. 
Each study participant was followed for 15 years after 
transplantation. 
 The patients’ clinical data in their medical records 
relevant to post-KTx hypertension were age at 
KTx, sex, causes leading to ESKD, presence or 
absence of preemptive KTx, transplant era based 
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on immunosuppression protocol, donor source, 
immunosuppressant dosage at 5 years post-KTx, 
presence or absence of acute rejection episodes 
within 5 years post-KTx, presence or absence of 
antihypertensives at pre-KTx/1 year post-KTx/10 years 
post-KTx/15 years post-KTx, hypertension-associated 
comorbidities including metabolic vascular risk factors 
（overweight, hypertriglyceridemia, glucose intolerance） 
and experience of transition from pediatric to adult 
KTx care both at 10 years post-KTx, and the eGFR 
at 1 year post-KTx /5 years post-KTx/10 years post-
KTx/15 years post-KTx. Cyclosporine A and tacrolimus 
were measured using a chemiluminescent enzyme 
immunoassay. Overweight, hypertriglyceridemia, and 
glucose intolerance were defined as more than 120% 
of the gender and height-adjusted median based on the 
Japanese pediatric data［24］, more than 150 mg/dL, and 
more than 110 mg/dL of the fasting plasma glucose, 
respectively. The eGFR was calculated according to the 
formula for the Japanese pediatric population［25］.
 ［Statistics］ Categorical results were analyzed using 
the chi-square test and Fisher’s exact test （for small 
sample sizes） when comparing variables between 
HRs and NRs. Numerical results were analyzed 
using Student’s t test or the Mann-Whitney U test as 
appropriate and presented as the mean or median and 
standard deviation （SD） or interquartile range. P＜
0.05 was considered to be statistically significant. All 
statistical analyses were conducted using Microsoft 
Excel version 16051.11727.20230.0 
Ⅲ．Results
 Out of the 31 pediatric KTx recipients eligible for this 
study, at 5 years post-KTx, 17 （54.8%） were receiving 
one or more antihypertensives （HRs）, and 14 （45.2%） 
were not receiving any antihypertensives （NRs）. 
Initiation of antihypertensives was based on pediatric 
nephrologists’ decisions at individual recipients’ clinic 
visits by auscultatory blood pressure measurement 
using a mercury or an aneroid sphygmomanometer, 
resulting in adhering the most recent clinical practice 
guideline recommendations for all the study participants: 
stage 2 hypertension （≥95th percentile＋12mmHg 
or ≥140/90mmHg ［whichever is lower］ for children 
aged 1-13＞, and ≥140/90mmHg for children aged 
≥13）［26］. Table 1 summarizes the pre-KTx recipients’ 
characteristics. HRs were significantly older at KTx, 
more often had non-CAKUT causes leading to 
ESKD, and more instances of dialysis before KTx. All 
preemptive transplants were performed for recipients 
with hypoplastic dysplastic kidneys, a major CAKUT 
causing ESKD. All the latter patients were NRs. Table 2 
shows the transplant-specific conditions closely related 
to post-KTx hypertension. There was no significant 
difference between the HRs and NRs in terms of the 
transplant era, donor source, immunosuppressant 
administration at 5 years post-KTx or acute rejection 
episode within 5 years post-KTx. All living-related 
transplants gained immediate graft function, and 2 
cadaveric transplants showed excellent recovery from 
Table 1　Recipients’ Demographics
Variables Hypertensiven＝17
Normotensive
n＝14 P value
Age at KTx* 10.4（2.4-14.8） 3.3（1.6-10.9） ＜0.001**
Gender at KTx
Male（18） 10 8
0.72Female（13） 7 6
Causes leading to ESKD
CAKUT（15） 4 11
0.003**Non-CAKUT（16） 13 3
Preemptive KTx
Yes（6） 0 6
0.021**No （25） 17 8
KTx: kidney transplantation, y: year, ESKD: end stage kidney disease, CAKUT: congenital anomaly of kidney 
and urinary tract
*Data are presented as median （interquartile range）. **: statistical signiﬁcance
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Table 2　Transplant data associated with post-KTx HTN
Variables Hypertensive Normotensive P value
Transplant era by immunosuppression
　1987-1993（CsA＋AZA＋mPSL）（5） 2 3
　1994-99（CsA＋AZA＋mPSL＋ALG）（15） 9 6 0.55
　2000-02（Tac＋MMF＋mPSL＋Bx）（11） 6 5
Donor Source
LRD（29） 16 13 0.71
DD（2） 1 1
Immunosuppression at 5 -y post-KTx*
CsA（ng/ml） 62.1（31.2-73.6） 58.6（33.4-81.2） 0.57
Tac（ng/ml） 2.8（1.9-5.2） 3.1（2.1-5.6） 0.48
mPSL（mg/kg） 0.12（0.06-0.18） 0.11（0.04-0.20） 0.52
Acute rejection episodes ＜ 5 -y post-KTx
Yes（3） 2** 1**
0.58
No （28） 15　 13　
HTN: hypertension, CsA: cyclosporine A, AZA: azathioprine, mPSL: methylprednisolone, ALG: antilymphocyte 
globulin, Tac: tacrolimus, Bx: basiliximab, LRD: live related donor, DD: deceased donor
*CsA/Tac/mPLS data are presented as median （interquartile range）. **: acute rejection within 1-y post-KTx
Table 3　Long-term post-KTx HTN status
Variables Hypertensive Normotensive P value
with Antihypertensives
Pre-KTx
Yes （13） 7 6
0.67
No （18） 10 8
1-y post-KTx
Yes （12） 11 1
0.001*
No （19） 6 13
10-y post-KTx
Yes （18） 17 1
＜0.001*
No （13） 0 13
15-y post-KTx
Yes （19） 17 2
＜0.001*
No （12） 0 12
*: statistical signiﬁcance
Table 4　Comorbidities associated with Post-KTx HTN
Variables Hypertensive Normotensive P value
Overweight
Yes （16） 13 3
0.012*
No （15） 4 11
Hypertriglyceridemia
Yes （13） 11 2
0.009*
No （18） 6 12
Glucose intolerance
Yes （7） 4 3
0.617
No （24） 13 11
Experience of transition
Yes （14） 11 3
0.029*
No （17） 6 11
*: statistical signiﬁcance
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10 and 15 years post-KTx among the HRs in contrast to 
the stable eGFR among the NRs. 
Ⅳ．Discussion
 To the best of our knowledge, this is the first and 
the longest follow-up study to examine hypertension-
associated allograft dysfunction in Japanese pediatric 
KTx recipients over 15 years. The following two 
characteristics of the present study may clarify the 
effect of hypertension on long-term graft function: the 
description of actual and contiguous eGFR changes 
in functioning grafts instead of statistical estimates of 
graft survival rates, and the observation of every study 
participant equally for a period of 15 years. The results 
showed two important clinical observations: post-KTx 
hypertension was significantly associated with allograft 
dysfunction, and graft function prominently deteriorated 
after 10 years post-KTx. 
 First, this study demonstrated that hypertension 
at 5 years post-KTx, already distinct at one year post-
KTx and then persisted throughout the post-transplant 
course, was significantly associated with allograft renal 
dysfunction at 15 years post-KTx. It is conceivable that 
pediatric post-KTx hypertension is common within a 
year due to relatively high dosing of steroids/calcineurin 
inhibitors （CNIs） based on routine immunosuppressive 
protocols at the first year, and immunologic allograft 
conditions, e.g., acute rejection episodes/disease 
recurrence of primary kidney diseases resulting in 
higher maintenance dosing of immunosuppressants 
（steroids and CNIs）/consequent possible graft 
dysfunction, even in successful KTx gaining immediate 
graft function just after transplant surgery. However, 
an anuric period within a week. All 3 biopsy-proven 
acute rejection episodes occurred within a year and 
were reversed promptly with a few courses of bolus 
intravenous methylprednisolone administration. Table 3 
shows the pre- and post-KTx hypertension status. Most 
HRs continued to require antihypertensives throughout 
the post-KTx period whereas most NRs did not. Table 
4 shows the comorbidities, which may have caused and 
accelerated post-transplant hypertension, at 10 years post-
KTx; these comorbidities, except for glucose intolerance, 
occurred significantly more often in HRs than in NRs. 
Table 5 shows the mean eGFR at 4 post-KTx time points; 
all the data in both groups were normally distributed 
with a narrow SD. The eGFR did not differ significantly 
between the HRs and NRs until 10 years post-KTx 
although the decline in the eGFR became significant 
among the HRs towards the 15-year post-KTx time point. 
The Figure shows changes in the mean annual eGFR 
corresponding to chronological changes in graft function, 
including a steep downward slope in the eGFR between 
Table 5　Functional outcomes
Variables Hypertensive Normotensive P value
eGFR（ml/min/1.73m2）
1-year post-KTx 77.4（7.9） 76.2（7.8） 0.46
5-year post-KTx 68.6（7.3） 69.9（6.9） 0.31
10-year post-KTx 57.6（6.9） 58.8（5.4） 0.25
15-year post-KTx 24.3（4.1） 53.4（5.6） ＜0.001*
eGFR: estimated glomerular ﬁltration rate
Data are normally distributed and presented as Mean （SD）. *: statistical signiﬁcance
Fig. 1　 Post-transplant graft function over time presented 
as the annual mean estimated glomerular filtration 
rate （eGFR）  
*: P＝0.31, **: P＝0.25, ***: P＜0.001 as indicated in 
Table 5
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hypertension （proven by LVH） before the normalization 
of blood pressure as measured by ABPM affects future 
graft outcomes. In our study, we defined hypertension 
based on the use of antihypertensives only, regardless 
of control status, whereas NRs were defined as those 
who were consistently non-hypertensive throughout 
their course, thus minimizing allocation bias［4,21］. 
Moreover, the distinct difference in eGFR decline over 
15 years post-KTx between HRs and NRs suggests that 
hypertension per se may be considered to be a cause 
rather than a consequence of long-term renal allograft 
dysfunction. 
 Second, our continuing longitudinal observation 
revealed that the hypertension-associated decline in 
eGFR became more distinct after 10 years post-KTx 
than earlier. Previous, long-term studies statistically 
estimated the graft survival rate in recipients with 
hypertension at 15  to 20  years post-KTx to be 
approximately 40% of that at 5 to 10 years post-
KTx［4,23］; however, unlike our study, these studies 
did not specify the allograft functioning status in the 
surviving grafts. The steeper eGFR decline seen in HRs 
between 10 and 15 years post-KTx may underscore 
the importance of longer periods of observation （＞10 
years） to evaluate how hypertension per se influences 
allograft outcomes. The accelerated eGFR deterioration 
after 10 years post-KTx could be the late effect of 
both metabolic vascular risk factors and transition-
related non-adherence （NA） issues, precipitating 
hypertension. The metabolic vascular risk factors 
consisting of obesity, dyslipidemia and diabetes have 
been shown to be frequent in recipients with older age 
at KTx （around their pubertal periods）, to coexist with, 
and to aggravate hypertension very often. This process 
as a whole, as metabolic syndrome, was significantly 
associated with allografts’ significant but slow-and-
steady eGFR decline in pediatric recipients via short- 
and medium-term observations within several years, 
although the impact of metabolic syndrome on long-
term graft outcomes （＞10 years） has yet to be 
determined［15,18,27,28］. Moreover, unstable, post-
transition adherence to antihypertensives in adolescents 
and young adults （AYA） with KTx reportedly resulted 
instead of resolving these episodes mostly within 12 
months post-KTx, primary hypertension secondary to 
lifestyle issues in pediatric recipients with older age 
at KTx emerges at as early as 1 year post-KTx. In 
addition, secondary hypertension due to aforementioned 
immunologic events can be more prominent at 1 year 
after KTx and can persist afterwards, depending upon 
the severity of the events［14］. Previous studies showed 
mix results in long-term （＞10 years） renal allograft 
outcomes associated with hypertension［4,5,11,12,20-
23］. One possible explanation of this is the interstudy 
difference in the cohort demographics; reports showing 
no significant association between hypertension and 
graft outcomes focused on non-immunologic diseases 
causing ESKD （e.g., CAKUT）,  lower pre-KTx 
hypertension prevalence, and younger age at KTx
［5,11,12,22］; in contrast, studies reporting opposite 
outcomes focused on non-CAKUT primary kidney 
diseases （e.g., focal segmental glomerulosclerosis 
［FSGS］）, greater prevalence of pre-KTx hypertension, 
and older age at KTx［4,20,21,23］.  In our study, 
although these parameter variables were comparably 
distributed in the cohort, HRs were significantly more 
numerous among older individuals and occurred more 
frequently with non-CAKUT diseases than in NRs 
（Table 1）. Another possible reason is the difference in 
the definition of post-KTx hypertension, based on any 
of the following: （i） ABPM［5,11］, （ii） office blood 
pressure measurement at patient visit［23］, （iii） use of 
antihypertensive agents［4,21］, （ii）＋（iii）［24］or （i）＋
（ii）＋（iii）［12,20］. Both short-term ［16,17］ and long-
term studies have demonstrated clearly that defining 
post-KTx hypertension by the use of antihypertensives 
leads to a significant association between hypertension 
and poor graft survival［4,21］. One report emphasizing 
the superiority of defining post-KTx hypertension based 
on the use of antihypertensives showed an LVH co-
occurrence rate of 37% in kidney transplant recipients 
with good control of hypertension due to the use of 
antihypertensives as measured by ABPM［12］. This 
may help to explain that good control of hypertension 
as measured by ABPM does not necessarily translate 
into favorable graft survival results; indeed, chronic 
17Hypertension-associated long-term pediatric renal allograft dysfunction
adult post-KTx services［8,14,15］. However, to date, 
whether such meticulous long-term blood pressure 
control, starting immediately after pediatric KTx, leads 
to the preservation of long-term renal allograft function 
remains unclear.
 This study has several limitations. First, the present 
observational study used a small sample size and 
analyzed the data retrospectively without randomization. 
Different immunosuppressants and antihypertensives 
were included without any analysis of possible 
differences in their individual effects. Second, only 
recipients with functioning grafts were included; 
therefore, the effect of hypertension on rapid graft loss 
was not investigated. However, excluding graft failure 
in this study may have shed light on how hypertension 
itself affects allograft renal function in the long run. 
Third, the definition of hypertension in this study was 
based on the use of antihypertensives only, rather than on 
actual measurements of blood pressure; however, given 
that the results of previous studies have demonstrated 
that graft function may not necessarily be preserved 
by the current status of well-controlled hypertension if 
there is a long history of uncontrolled hypertension, the 
definition of hypertension in the present study may not 
be inappropriate. 
 In conclusion, the present study showed that 
hypertension significantly influenced long-term renal 
allograft function over 15 years in Japanese pediatric 
KTx recipients. The eGFR decline rate accelerated 
after 10 years post-KTx. Our findings emphasize 
the importance of strict and prolonged post-KTx 
hypertension monitoring and control in pediatric 
recipients, especially among patients with older age 
at KTx, non-CAKUT primary diseases, metabolic 
syndrome related conditions, and transition to adult 
care. In the future, further studies with larger sample 
sizes should be conducted to elucidate how the 
aforementioned holistic approach to blood pressure 
control can improve long-term renal allograft outcomes 
in pediatric KTx recipients.
in suboptimal blood pressure control and poor long-
term graft outcomes［6,9,13］. In the present study, these 
comorbidities at 10 years post-KTx were significantly 
more prevalent among HRs than among NRs （Table 4）. 
Possible concrete explanations for this intense and long-
lasting relationship between HRs and the comorbidities 
include that HRs predominantly consisted of （i） older-
age-at-KTx recipients who could have become obese/
hyperlipidemic/hypertensive after KTx due to early-
developed and long-running undisciplined high caloric/
salty eating habits by liberalized dietary restrictions/
improved appetite without appropriate supervision and 
possible NA to antihypertensives, being established 
and consolidated by experience of transition, together 
with pubertal and post-pubertal psychosocial/emotional 
conflicts, （ii） more non-CAKUT primary diseases, 
represented by immunologic glomerular conditions with 
possible recurrence in renal allografts （e.g., FSGS）, in 
that concomitant higher maintenance dosing of steroids/
CNIs and graft dysfunction by the episodes could have 
evoked obesity/dyslipidemia/diabetes/hypertension, 
and （iii） no recipients with preemptive KTx, which has 
shown better long-term control of blood pressure, body 
weight, lipid metabolism, blood glucose, and health 
related quality of life by escaping uremia and dialysis
［28］, in that uremia and dialysis even only a little 
more than 1 year could have caused and sustained these 
comorbidities after KTx. Taken together, our results 
suggest that post-KTx hypertension, especially in the 
AYA age group, exacerbated by coexisting metabolic 
vascular risk factors and transition-related NA issues, 
may play an important role in late accelerated loss of 
graft function more than a decade after KTx. 
 Given these comorbidities, such as metabolic 
vascular risk factors and NA with transition in AYA 
age group, a number of studies have described the 
need for active, systems-based trials for improved 
blood pressure control among pediatric KTx recipients 
and have recommended strict ABPM, periodic LVH 
imaging by echocardiogram, better selection of 
antihypertensives, lifestyle modification programs, 
such as dietary counseling and daily exercise guidance, 
and structured transition programs from pediatric to 
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